Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Federal Trade Commission
Chinese Patent Office
Julphar
Fish and Richardson
Cerilliant
Argus Health
Chubb

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,126,931

« Back to Dashboard

Which drugs does patent 9,126,931 protect, and when does it expire?

Patent 9,126,931 protects ALECENSA and is included in one NDA.

This patent has forty patent family members in thirty-five countries.
Summary for Patent: 9,126,931
Title:Tetracyclic compound
Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: ##STR00001## (meanings of the symbols that are included in the formula are as given in the specification).
Inventor(s): Kinoshita; Kazutomo (Kanagawa, JP), Asoh; Kohsuke (Kanagawa, JP), Furuichi; Noriyuki (Kanagawa, JP), Ito; Toshiya (Kanagawa, JP), Kawada; Hatsuo (Kanagawa, JP), Ishii; Nobuya (Kanagawa, JP), Sakamoto; Hiroshi (Kanagawa, JP), Hong; WooSang (Gyeonggi-do, KR), Park; MinJeong (Gyeonggi-do, KR), Ono; Yoshiyuki (Shizuoka, JP), Kato; Yasuharu (Shizuoka, JP), Morikami; Kenji (Shizuoka, JP), Emura; Takashi (Shizuoka, JP), Oikawa; Nobuhiro (Kanagawa, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:13/377,300
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 9,126,931

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,126,931

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2009-139691Jun 10, 2009
PCT Information
PCT FiledJune 09, 2010PCT Application Number:PCT/JP2010/059785
PCT Publication Date:December 16, 2010PCT Publication Number: WO2010/143664

Non-Orange Book US Patents Family Members for Patent 9,126,931

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,440,922 Tetracyclic compound ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,126,931

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2585622 ➤ Sign Up
Russian Federation 2011154150 ➤ Sign Up
Serbia 20110548 ➤ Sign Up
Portugal 2441753 ➤ Sign Up
Poland 2441753 ➤ Sign Up
Peru 10652012 ➤ Sign Up
New Zealand 597477 ➤ Sign Up
Norway 2017026 ➤ Sign Up
Lithuania PA2017017 ➤ Sign Up
South Korea 101351120 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Teva
Deloitte
Argus Health
Cantor Fitzgerald
Citi
Accenture
McKinsey
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot